European Biotech Acquisition Stock Net Income
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess European Biotech's long-term financial health and intrinsic value.
European |
European Biotech Acquisition Company Net Income Analysis
European Biotech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current European Biotech Net Income | 342.89 K |
Most of European Biotech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, European Biotech Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, European Biotech Acquisition reported net income of 342.89 K. This is 99.97% lower than that of the Financial Services sector and significantly higher than that of the Shell Companies industry. The net income for all United States stocks is 99.94% higher than that of the company.
European Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses European Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of European Biotech could also be used in its relative valuation, which is a method of valuing European Biotech by comparing valuation metrics of similar companies.European Biotech is currently under evaluation in net income category among its peers.
European Fundamentals
| Current Valuation | 164.04 M | |||
| Shares Outstanding | 13.21 M | |||
| Shares Owned By Institutions | 72.30 % | |||
| Number Of Shares Shorted | 258.83 K | |||
| Price To Earning | 66.40 X | |||
| Price To Book | 1.34 X | |||
| EBITDA | 342.89 K | |||
| Net Income | 342.89 K | |||
| Cash And Equivalents | 308.1 K | |||
| Cash Per Share | 0.02 X | |||
| Current Ratio | 1.11 X | |||
| Book Value Per Share | (0.37) X | |||
| Cash Flow From Operations | (514.79 K) | |||
| Short Ratio | 0.05 X | |||
| Earnings Per Share | 0.02 X | |||
| Market Capitalization | 183.5 M | |||
| Total Asset | 129.75 M | |||
| Net Asset | 129.75 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in European Stock
If you are still planning to invest in European Biotech Acq check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the European Biotech's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |